Nanobiotix (NASDAQ:NBTX – Get Rating) and Earth Science Tech (OTCMKTS:ETST – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.
Profitability
This table compares Nanobiotix and Earth Science Tech's net margins, return on equity and return on assets.
Get Nanobiotix alerts:| Net Margins | Return on Equity | Return on Assets | |
| Nanobiotix | N/A | N/A | N/A |
| Earth Science Tech | 22,466.90% | -168.23% | 2,554.45% |
Valuation and Earnings
This table compares Nanobiotix and Earth Science Tech's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanobiotix | $3.13 million | 44.01 | -$55.61 million | N/A | N/A |
| Earth Science Tech | $10,000.00 | 89.07 | $3.17 million | N/A | N/A |
Analyst Recommendations
This is a breakdown of current recommendations for Nanobiotix and Earth Science Tech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanobiotix | 0 | 1 | 0 | 0 | 2.00 |
| Earth Science Tech | 0 | 0 | 0 | 0 | N/A |
Risk and Volatility
Nanobiotix has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Institutional & Insider Ownership
10.0% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Earth Science Tech beats Nanobiotix on 5 of the 9 factors compared between the two stocks.
About Nanobiotix
(Get Rating)
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
About Earth Science Tech
(Get Rating)
Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, nutrition, supplement, cosmetic, and alternative medicine worldwide. The company focuses on delivering nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging, and overall wellness. Its products include hemp oils, vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods, and other products. The company markets its products in a range of formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs through its retail store, clinics, pharmacies, as well as through online. It also provides medical equipment and devices. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. The company was incorporated in 2010 and is headquartered in Doral, Florida.
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.